To The Moon

$CELH DIAGONAL 260320/251003 CALL 50.0/CALL 57.0$ CELH: take profit from these 3 call spreads.  Bought long call at strike $50 and selling shorter dated call at $57 that will expire on 3rd Oct.  However CELH trades closer to $60 today so the short call are in the money.  Since it was a paired trade, decided to close the entire pair and secured the profit.  The long call was bought during the dip so there are already profitable as of now, but just within a short period of time so the long call extrinsic value were mostly still intact. 

$S&P 500(.SPX)$ $NASDAQ(.IXIC)$ The market is buzzing on October 3, 2025, with the S&P 500 at 6,650, Nasdaq at 22,200, and Bitcoin at $128,500, riding the Fed’s 25 bps cut and Trump’s trade thaw with China. The VIX at 13.80 signals calm, but oil at $74.20/barrel and tariff talks add nuance. Key catalysts include U.S. unemployment data at 12:30 PM UTC (forecast 4.2% from 4.3%), which could sway EUR/USD and dollar strength. With 81% of S&P 500 firms beating estimates, today’s session could extend the rally or spark a pause. What movements are shaping the market, which stocks demand attention, and what trading plays can you seize? This comprehensive guide breaks down the catalysts, top picks, an

$Netflix(NFLX)$ $S&P 500(.SPX)$ $NASDAQ(.IXIC)$ $Tesla Motors(TSLA)$ Netflix shares (NFLX) have plunged 5% over five days, with the stock holding at $1,162.53 as of today, per the finance card above, erasing nearly $30 billion in market cap since Elon Musk’s call on X to cancel subscriptions ignited widespread cancellations. The S&P 500 slipped to 6,500, reflecting broader caution ahead of unemployment data at 12:30 PM UTC. Musk’s influence, with his 226 million followers amplifying the boycott, has pressured Netflix amid content controversy, notably over “Dead End: Paranormal Park.” Can the stock stabilize, or

🟩 📈 Ready to navigate SGX’s record highs and uncover what lies ahead for investors? Join Iggy in this packed-with-insights episode as we dive into the latest SGX movements, analyze the Straits Times Index near its all-time high, and shed light on the key drivers behind these trends. Whether you're tracking big-cap developers like UOL and Singland, keeping tabs on First Resources’ portfolio cleanup, or intrigued by Keppel’s game-changing Bifrost subsea cable, this video is your ultimate guide. 🌟 We break down major developments, including Singapore's latest en bloc deals, digital infrastructure milestones, and even autonomous buses shaping the future of mobility. Plus, what does it all mean for your investment decisions? From property cycles to global macro factors, find out how to position

I used to struggle most with #2 (letting small losses turn into big ones) and #9 (hoping for a rebound), especially early on when I believed “it’ll come back.” That mindset turned manageable losses into painful lessons. The market eventually taught me that capital preservation is priority one, and protecting the downside is what allows you to stay in the game. Over time, I’ve grown to lean strongly toward strict stop-losses. They help remove emotion and force accountability. When a trade hits my predefined limit, I exit; no hesitation, no bargaining. I’ve also learned to size positions smaller so stops don’t feel punitive. One turning point came from a tech trade that fell 40% while I kept averaging down, convinced it would recover. It never did. That loss reshaped my approach entirely; I

🟩 📉 **SG Banks Drop! Why I'm Holding DBS, OCBC & UOB** 📈 Join Iggy from The Investing Iguana as he sheds light on why Singapore's big banks—DBS, OCBC, and UOB—remain solid despite the recent market dip. Whether you're feeling jittery or seeking clarity, this video is packed with insights to help you navigate the chaos with confidence. ✨ Here's what you'll learn: - 📊 The impact of the Fed rate cut and what it means for Singapore banks. - 🏦 Why DBS, OCBC, and UOB are built to weather storms with their unique strengths and MAS regulations. - 💡 Iggy's "balance framework" for making smart, steady investment decisions. - 💸 Tips to leverage CPF/SRS accounts, stagger your buys, and build sustainable long-term wealth. Singapore banks aren't just financial giants—they’re anchors of stability wit

The answer is yes, I have made a lot of mistakes over the years. One I'm reminded of very recently comes to mind. I have been mentioning my nephew with stock trading and finance in general. Now let's back up a bit, my nephew is 38 years old... so a spring chicken to me, but not to many. He was never taught about money, had to figure it out as he went along, much like me in the early years of investing. Buts lets go to the deadly mistakes I made when I started investing 35 odd years ago. Penny dreadful stocks. My nephew is reminding me of this big time. If you have say $1,000 you mite only be able to buy 1 share or two, or three in a company like $Microsoft(MSFT)$  or $Alphabet(GOOG)$ for example. So

It's going to break the $200 mark within days. The best is yet to come as Jack Ma will spur    the growth of AI and ensure that the company is in line with China's government expectation. Who will emerge the victory for this challenge    is yet to see??? The shortfall is still on the       chips and they need good source of supplies     in order to overcome the challenges from         West. Be patient and wait for the big windfall of the century. 

MicroStrategy (MSTR): Riding the Bitcoin Wave to New Heights by January 2026 As we hit the home stretch of 2025, the crypto market is buzzing with optimism, and few stocks embody that energy quite like MicroStrategy (MSTR). With Bitcoin flirting around $111,000 and showing no signs of slowing down, MSTR—often dubbed the “Bitcoin proxy” for retail investors—has been on a tear. Closing at around $338 on October 1, the stock is up over 150% year-to-date, fueled by the company’s aggressive Bitcoin accumulation strategy. 0 But with just three months until January 2026, is there more upside? Absolutely. In my view, MSTR could easily climb to $370–$450 by then, turning heads and padding portfolios along the way. The Bitcoin Backbone: Why MSTR Moves with the Market MicroStrategy’s fortunes are ine

For long-term investing, it is usually not about just one metric like ROE (Return on Equity) or P/E (Price-to-Earnings ratio). Instead, investors often look at a combination of factors to form a holistic view of a company’s quality, growth potential, and valuation. In this article, I would like to share how I would break it down: 1. Quality of the Business ROE (Return on Equity): Measures how efficiently a company uses shareholders’ money to generate profits. High and consistent ROE (say, >15%) can signal strong competitive advantages (a “moat”). ROIC (Return on Invested Capital): Similar to ROE but accounts for debt as well. Often considered a cleaner measure of management quality. Margins (Gross/Operating/Net): Strong and stable margins often point to pricing power. ROE/ROIC tell you

🚨🚨🚨The market analysis for October 3, 2025, shows a generally positive sentiment, particularly in the US and global equities, despite some economic headwinds. Here is a summary of the key market movements and factors: US Stock Market:  * Continued Bullish Trend: The S&P 500 ($6,719.59) and Nasdaq composite (22,796.82) continued to trade near or at fresh all-time highs, largely driven by optimism around Artificial Intelligence (AI) and growing expectations of a more dovish Federal Reserve (Fed).  * S&P 500 (SPX 500): Notched another fresh all-time high of 6,745 (CFD index) during the European session, with analysts suggesting a potential medium-term target of 6,800-6,850. The market has largely brushed aside concerns over a potential US government shutdown, focusing instea

Introduction: A Hidden Gem in Biotech In the volatile world of biotechnology investing, Plus Therapeutics, Inc. (NASDAQ: PSTV) stands out as a compelling opportunity. This clinical-stage company, based in Houston, Texas, is developing cutting-edge targeted radiotherapies for central nervous system (CNS) cancers, such as leptomeningeal metastases (LM), a rare and deadly condition. With its lead asset, Rhenium NanoLiposome (REYOBIQ), and a diagnostic platform, CNSide Test, PSTV is carving a niche in a high-demand, underserved market. At its current price of $0.68, significantly below analysts’ consensus target of $7.88, PSTV offers a rare chance for explosive returns. Here’s why this stock deserves your attention. 1. Company Snapshot: Innovating in a Niche Market Plus Therapeutics focuses on